|
Summary Information: Savara Inc. Common Stock NASDAQ:SVRA |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization.
__The following are links to various summary and news pages for __Savara Inc. Common Stock [ SVRA ]. __Note: Some Links might not have information for the company. |
|